Affimed (AFMD) – Analyst Ratings
-
Affimed Therapeutics (AFMD) PT Raised to $5 at Stifel
-
Berenberg Assumes Affimed Therapeutics (AFMD) at Buy, 'low-risk/high-reward opportunity'
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to AFMD Stock Lookup